Rockefeller Capital Management L.P. - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.

Quarter-by-quarter ownership
Rockefeller Capital Management L.P. ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$3,380,375
-18.1%
74,474
+1.2%
0.01%
-18.8%
Q2 2023$4,129,546
+118225.1%
73,558
-4.7%
0.02%
+6.7%
Q1 2023$3,490
+6.3%
77,176
-4.4%
0.02%
-6.2%
Q4 2022$3,283
-99.9%
80,766
-15.4%
0.02%
-50.0%
Q3 2022$6,235,000
+571.9%
95,432
+524.3%
0.03%
+540.0%
Q2 2022$928,000
-37.6%
15,286
-35.6%
0.01%
-28.6%
Q1 2022$1,488,000
-17.0%
23,718
+0.2%
0.01%
-12.5%
Q4 2021$1,792,000
-6.3%
23,662
+38.4%
0.01%
-20.0%
Q3 2021$1,912,000
+233.7%
17,093
+382.4%
0.01%
+233.3%
Q2 2021$573,000
+2.3%
3,543
-22.9%
0.00%
-25.0%
Q1 2021$560,000
-37.3%
4,596
-21.3%
0.00%
-42.9%
Q4 2020$893,000
+136.9%
5,838
+29.2%
0.01%
+75.0%
Q3 2020$377,000
+38.1%
4,517
+21.6%
0.00%
+33.3%
Q2 2020$273,000
+279.2%
3,715
+116.6%
0.00%
+200.0%
Q1 2020$72,000
-35.7%
1,715
-7.1%
0.00%0.0%
Q4 2019$112,000
+45.5%
1,847
-1.3%
0.00%0.0%
Q3 2019$77,000
-17.2%
1,872
-5.4%
0.00%0.0%
Q2 2019$93,000
+31.0%
1,9790.0%0.00%0.0%
Q1 2019$71,000
+24.6%
1,9790.0%0.00%0.0%
Q4 2018$57,000
-35.2%
1,9790.0%0.00%0.0%
Q3 2018$88,000
-24.1%
1,9790.0%0.00%
-50.0%
Q2 2018$116,0001,9790.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2020
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders